Xcell and Labcorp team up to develop cell and gene therapies

0
199

It has been announced that Labcorp will collaborate with the biotechnology company xCell Biosciences to advance the development of new cell and gene therapies (CGTs).

As a result of the alliance, the companies will work together on a variety of projects to improve the safety and efficacy of CGTs.

It supports Labcorp’s commitment to expanding its worldwide, complete CGT expertise while helping pharmaceutical and biotechnology companies speed up the development of treatments.

CGTs alter the genes of a person in order to treat diseases, either by disabling or substituting a disease-causing gene, or by introducing a new or modified cell or gene into the body.

Many diseases, from Parkinson’s to solid tumours to rare diseases to blood-based malignancies, are being studied in the hope that one of these treatments will be effective.

Xcellbio’s AVATAR incubator system will be used by the partnership’s projects to develop research-grade CAR-T cell material that can be used to kill cancer cells.

This initiative will help demonstrate the importance of knowing the parameters of the tumour microenvironment in order to create CAR-T cells that perform at a higher level.

In addition, the technology will be used to adapt cancer cells to more physiological conditions and extend 3D modelling for in vitro CAR-T testing.

Following a strategic investment in Xcellbio made by Labcorp in November of last year, a new partnership has been formed.

According to Dr. Maryland Franklin, the head of the Labcorp cell and gene therapy enterprise and vice president, “Labcorp is firmly committed to assisting our clients in providing new treatment options to patients in need while also revolutionizing the future of medicine through the use of cell and gene therapies.”

“The combination of the scale and breadth of our enterprise-wide CGT solutions with Xcellbio’s powerful technology provides us with an opportunity to enhance and accelerate the CGT development experience.”

Cytiva provides support for cell and gene therapy coverage in the field of pharmaceutical technology.

Editorial content is created in an independent manner and adheres to the highest standards of journalistic ethics and integrity. The creation of editorial content is not influenced by topic sponsors in any way.

Also read: Minicorns and Leaders of Wearable Technology Chosen by Somatix

Previous articleChief Growth Officer John Avalos named by Arcfield and Chief Technology Officer Ted Fidder named by Arcfield
Next articleLatest earnings report sends stocks tumbling on Wall Street
Zaid Quraishi
My name is Zaid Quraishi. I pride myself on being a meticulous and organized individual who has done his Bachelors in Medical Technology and currently pursuing my Master's in the same course from Sher-e-Kashmir Institute of Medical Sciences. I belong to the beautiful valley of Kashmir, and my hometown is Srinagar. I am the elder sibling of my younger brother. As far as my strengths are concerned, I am effectively communicative, optimistic, reliable, a team player, and time-efficient. My weaknesses are that I am an honest person and I tend to be blunt, and sometimes, I like to work alone. I am passionate about content writing, online gaming, and learning new things, especially languages (currently German). I have written two papers for my University degree, which helped me immensely in learning how to write effectively. I am confident in my writing skills, and I can effectively pour my thoughts out in writing and express myself so that the reader relates to it and is intrigued by the content. I love to play with my pet cat, and she is a darling to me. The thing that I dislike the most is being distracted when you are in the zone. Currently, I am a content writer in a dynamic work environment at Shouzy, ready to improve readers' satisfaction and increase retention levels.

LEAVE A REPLY

Please enter your comment!
Please enter your name here